Our Board of Directors are built to help guide our vision, bringing extensive experience in clinical drug development with a keen perspective on emerging technologies, next generation analytics and the application of precision medicine. Click to expand.
Edwina Baskin-Bey, MD
Edwina Baskin-Bey, MD is an international biopharmaceutical veteran with more than 18 years experience in academia and industry. Dr. Baskin-Bey is Chief Medical Officer and Executive Board Member at Nanobiotix, a Paris, France-based clinical-stage nanomedicine company pioneering new approaches for the treatment of cancer.
Previously, Dr. Baskin-Bey was Chief Medical Officer of Innocrin Pharmaceuticals, an oncology-focused pharmaceutical company, where she also led the development and implementation of the clinical and corporate strategy, covering many pivotal roles and responsibilities. Dr. Baskin-Bey joined Innocrin from Janssen Oncology (Johnson & Johnson), where she steered both early- and late-stage oncology global development programs for in-licensed products. Precursory to, whilst based in the EU, she was responsible for life cycle management of several large global oncology programs as well as Head of European Medical Affairs for Astellas Pharma.
Dr. Baskin-Bey received a bachelor’s degree from Hunter College and a medical degree from Mount Sinai/New York University School of Medicine. She was trained in general surgery and oncology at The Mayo Clinic in Rochester, MN, and in basic science research principles by the National Institute of Health.
Vern Davenport is Partner at NovaQuest Capital Management and has more than 35 years experience of building and transforming healthcare technology and services companies. He is Investment Committee Member at NovaQuest Private Equity.
Before NovaQuest, Vern was CEO and Board Member at Medfusion. Previously, Vern was Chairman and CEO of Medquist before and after the privatization of the company. He rebranded the company to M*Modal and led the take private process, resulting in the sale to One Equity Partners.
Vern’s experience includes President, Allscripts; CEO, Misys Healthcare; GM & EVP, Kodak Health Group (now Carestream Health) and executive leadership roles at Siemens and Shared Medical Systems. He also was at IBM for 11 years, serving in sales leadership and executive management positions.
Vern received an MBA and a BSBA in Business from East Carolina University. He serves on the East Carolina Board of Trustees and the WakeMed Health and Hospitals Boards and has held other board positions.
Christine Dingivan, MD
Dr. Christine Dingivan has more than 20 years of industry experience across research & development, commercial and digital disciplines with responsibilities that span drug development, corporate strategy and digital innovation. Most recently, she served as an executive in the Global Drug Development division at Novartis, responsible for leading portfolio strategy and building the digital innovation strategy.
Prior to Novartis, Christine was at Pharmaceutical Product Development, serving as Global Head, Strategic Client Solutions and Chief Medical Officer and as Executive Committee member. Christine started her industry career at MedImmune, holding diverse roles of increasing responsibility ultimately as SVP, Clinical Research and Operations where she was responsible for clinical research efforts and development programs across multiple therapeutic areas, global clinical operations, biostatistics, data management, regulatory, HEOR and medical affairs.
Dr. Dingivan received a Bachelor of Engineering – Bioengineering and Chemical Engineering from the University of Pennsylvania and a medical degree from Dartmouth Medical School and trained in General Surgery at Northwestern University School of Medicine.
Nick Dyer is the CEO of Catalyst Clinical Research, LLC and has more than 21 years experience in healthcare and life sciences. Previously, Nick was President of Novella Clinical and also served as Chief Commercial Officer. At Novella, Nick fervently embraced the need for therapeutically-focused CRO solutions interlaced with a flexible, small biotech, customer service model. Nick also led clinical operations, finance, IT, and sales/marketing functions for Quintiles (IQVIA) and Pharmaceutical Product Development. Previously, Nick led a finance group for a large UK based hospital following a three-year postgraduate healthcare management program with the UK National Health Service.
Nick received a First Class Bachelor’s Degree in Economics from the University of Greenwich, London and qualified as a Chartered Public Finance Accountant in 1995.
Jeffrey Kasher, PhD
Dr. Jeff Kasher is a pharmaceutical development executive with more than 30 years of experience. He focused on improving clinical outcomes, bringing patients and research sites into the drug development process, and decreasing time to market. He is a top 20 Innovators Changing the Face of the Clinical Trials Industry and was recognized on The Medicine Maker Power List 2015.
Jeff spent 28 years at Eli Lilly and Company serving in various leadership positions, including VP of Clinical Innovation and Implementation and VP and Chief Operation Officer of the Global Clinical Development Organization.
Jeff was a Post Doctoral Fellow at the Yale University School of Medicine and received a PhD, Pharmacology from the State University of New York Upstate Medical University. He received a BS in Chemistry from Franklin & Marshall College. Jeff currently serves as Board Director of Javara Research, an integrated research organization, and is President of Patients Can’t Wait LLC.
Jeff Edwards has over 18 years of investment experience and is a Partner at NovaQuest Capital Management. He is responsible for transaction origination, investment policy, fundraising, and the day-to-day management of NovaQuest Capital Management. In addition, he directs the Private Equity team in acquisitions, divestitures, and oversight of portfolio companies.
Prior to joining NovaQuest, Jeff co-led the Principal Investment Private Equity program at the Teacher Retirement System of Texas, leading the efforts in the Healthcare and Industrial sectors across a variety of geographies. In that role, he was responsible for making investment decisions, deal origination, as well as portfolio construction and portfolio management.
Jeff’s previous experience also includes M&A advisory work for Raymond James Capital Markets, focusing on middle-market companies. He also worked for State Street Global Markets (SSGM). His efforts were focused on private equity fund formation, portfolio management, and investment due diligence. Before moving back to the capital markets sector, Jeff worked in finance and administrative roles in the healthcare industry with Carolinas HealthCare Systems and HCA, Inc. He started his career with the middle market investment bank RW Baird.
Jeff received an MBA from the University of North Carolina at Chapel Hill, an MSF from Boston College, and a BA from the University of Tennessee at Knoxville. He is also a CAIA Charter Holder.
Amelia Wall Warner, PharmD, RPH
Amelia Wall Warner has more than 20 years of healthcare and management experience. Currently, Amelia is the Founder and CEO of Clinical Trial Concepts, Inc., specializing in SaaS for the pharmaceutical industry.
She also founded Global Specimen Solutions, Inc, an innovative specimen management CRO and Informatics Company, and sold the company to LabCorp in December 2017. Previously, Amelia served as Head of Clinical Pharmacogenomics/ Clinical Specimen Management for Merck and Head of Pharmacogenomics for the Children’s Hospital of Philadelphia.
Amelia is also the former CEO and President of Gentris Corporation, successfully leading the operational and financial turnaround of the company that resulted in the acquisition by Cancer Genetics, Inc.
Amelia received her doctorate from University of North Carolina and completed residency and fellowship training at St Jude Children’s Research Hospital. She has held numerous leadership roles and won industry awards including invited PhRMA representative to ICH E16 and Chair (selected by her peers), Industry Pharmacogenomics Working Group.